KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accounts Payables: 2017-2025

Historic Accounts Payables for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $10.9 million.

  • Aquestive Therapeutics' Accounts Payables rose 43.49% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 43.49%. This contributed to the annual value of $10.3 million for FY2024, which is 15.25% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Accounts Payables is $10.9 million, which was down 9.09% from $12.0 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Accounts Payables peaked at $12.4 million during Q1 2023, and registered a low of $5.7 million during Q2 2024.
  • Over the past 3 years, Aquestive Therapeutics' median Accounts Payables value was $10.5 million (recorded in 2024), while the average stood at $10.1 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Accounts Payables plummeted by 59.21% in 2021, and later soared by 109.81% in 2025.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Accounts Payables stood at $8.3 million in 2021, then grew by 19.63% to $9.9 million in 2022, then dropped by 10.26% to $8.9 million in 2023, then rose by 15.25% to $10.3 million in 2024, then skyrocketed by 43.49% to $10.9 million in 2025.
  • Its Accounts Payables was $10.9 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.3 million in Q1 2025.